How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

935 results for

Medication Causes of Dyspepsia

by
...
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

41. Prevention of Acute Nausea and Vomiting due to Antineoplastic Medication in Pediatric Cancer Patients

of administration of an antineoplastic therapy. Chemotherapy/antineoplastic therapy block: series of consecutive days that antineoplastic agents are given within a treatment plan or protocol Emetogenicity: the propensity of an agent to cause nausea, vomiting or retching. Please refer to the POGO Guideline classification of the acute emetogenic potential of antineoplastic medication in pediatric cancer patients for information regarding the emetogenicity of specific agents. 1, 2 ? High emetic potential: greater (...) Prevention of Acute Nausea and Vomiting due to Antineoplastic Medication in Pediatric Cancer Patients 1 Version date: February 28, 2013 Guideline for the Prevention of Acute Nausea and Vomiting due to Antineoplastic Medication in Pediatric Cancer Patients The POGO Antineoplastic–induced Nausea and Vomiting Guideline Development Panel: L. Lee Dupuis MScPhm, ACPR, FCSHP Sabrina Boodhan BScPhm, ACPR Mark Holdsworth PharmD, BCOP Paula D. Robinson MD, MSc Richard Hain MD Carol Portwine MD, FRCPC

2013 SickKids Supportive Care Guidelines

42. Study of Motilitone to Treat Functional Dyspepsia

) or microscopic colitis. (6) Subject who had any of the diseases such as reflux esophagitis, gastroduodenal ulcer, gastric adenocarcinoma, esophageal adenocarcinoma, pancreatic disease, etc. that may be an organic cause of dyspepsia. (7) Subject with liver dysfunction (serum glutamic oxaloacetic transaminase/serum glutamic pyruvic transaminase is at least 2.5 times higher than ULN). (8) Subject with renal dysfunction (Serum creatinine level is at least 1.5 times higher than ULN). (9) Subject with a serious (...) ) Medications that can affect QT within last 2 weeks of randomization. (13) Subjects on herbal supplements for Functional Dyspepsia within last 2 weeks of randomization. (14) Subjects with gastric electric stimulator in place. (15) Subjects on narcotics or benzodiazepines within 7 days of randomization. (16) Subjects with score > 12 for anxiety or depression on the Hospital Anxiety and Depression Scale (HADS). (17) Vulnerable study population Contacts and Locations Go to Information from the National

2014 Clinical Trials

43. Effect of Genetic Association With Functional Dyspepsia and Mood Disorders

or medications that affect motility in past 4 weeks Organic disease as cause of dyspepsia (for subjects with dyspeptic symptom) Additional to healthy volunteer • Any gastrointestinal symptoms (including acid regurgitation, heartburn, epigastric pain, bloating sensation, constipation, abdominal pain, diarrhea) in the past 4 weeks Additional to FD patient Frequent (once or more per week) acid reflux or heartburn symptoms Helicobacter pylori (Hp) infection Contacts and Locations Go to Information from (...) Effect of Genetic Association With Functional Dyspepsia and Mood Disorders Effect of Genetic Association With Functional Dyspepsia and Mood Disorders - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Effect

2014 Clinical Trials

44. Efficacy of Motilitone on Gastric Emptying in Patients With Functional Dyspepsia: Evaluation Using MRI Method

, Samsung Medical Center. Recruitment status was: Not yet recruiting First Posted : May 30, 2014 Last Update Posted : November 25, 2014 Sponsor: Samsung Medical Center Information provided by (Responsible Party): Poong-Lyul Rhee, Samsung Medical Center Study Details Study Description Go to Brief Summary: Functional dyspepsia (FD) is a disorder characterized by chronic or recurrent upper abdominal pain or discomfort in the absence of a specific structural cause.1 Several mechanisms have been suggested (...) Responsible Party: Poong-Lyul Rhee, Clinical Professor, Samsung Medical Center ClinicalTrials.gov Identifier: Other Study ID Numbers: 2013-12-026 First Posted: May 30, 2014 Last Update Posted: November 25, 2014 Last Verified: November 2014 Keywords provided by Poong-Lyul Rhee, Samsung Medical Center: accommodation, emptying,motilitone Additional relevant MeSH terms: Layout table for MeSH terms Dyspepsia Signs and Symptoms, Digestive Signs and Symptoms

2014 Clinical Trials

45. SSRI Study for Functional Dyspepsia (SS)

, the correlation between plasma serotonin level in FD patients treated with SSRI is lacking in these studies. Indication: Functional dyspepsia patients Study center(s): Prince of Wales Hospital, Hong Kong Aims : To evaluate the effect of SSRI treatment on change of plasma serotonin level To evaluate the relationship between dyspeptic symptom and change of plasma serotonin level Study medication: Escitalopram (Lexapro) 5mg daily for first 2 weeks, and then 10 mg daily for 8 weeks versus Placebo for 10 weeks (...) Study design: Double-blind randomized placebo-controlled trial Number of subjects:72 - 36 patients (18 male and 18 female) and 36 age-and-sex-matched healthy controls Patient population: Functional dyspepsia patients age 18-60, with element of anxiety or depression Duration of study: 1 June 2013 - 30 November 2015 Primary variable(s): Change of serotonin and ghrelin level in blood plasma after medication treatment Secondary variable(s): Rate of adequate relief using global symptom assessment

2014 Clinical Trials

46. Clinical Improvement and in Quality of Life-Functional Dyspepsia-

Galdakao-Usansolo Study Details Study Description Go to Brief Summary: Functional dyspepsia (FD)is defined as the presence of symptoms thought to originate in the gastroduodenal region with no evidence of structural disease that is likely to explain the symptoms. The cause of this condition is unclear, not being a recognized treatment for it. The conventional treatments for those patients are symptom based. Unfortunately, these medications are not very effective. Patients with FD report poorer health (...) -behavioural therapy; and c) proressive-muscle relaxation according to Jacobson Behavioral: Psychological support Active Comparator: No psychological support Patients of this group only received the conventional medical treatment, not receiving any psychological support Other: No intervention Outcome Measures Go to Primary Outcome Measures : Change from baseline in DYSPEPSIA RELATED HEALTH SCALE (DRHS) [ Time Frame: Participants will be followed at the recruit momento (t0) after treatment (t1) and six

2013 Clinical Trials

47. A randomized controlled trial of brief psychoanalytic psychotherapy in patients with functional dyspepsia. (PubMed)

A randomized controlled trial of brief psychoanalytic psychotherapy in patients with functional dyspepsia. Functional dyspepsia (FD) is a common cause of upper gastrointestinal symptoms and discomfort. The present study aimed to assess the effectiveness of brief core conflictual relationship theme (CCRT) psychoanalytic psychotherapy on changing gastrointestinal symptoms, alexithymia, and defense mechanisms in patients with FD. In a randomized controlled trial study, 49 patients with FD were (...) randomly assigned to medical treatment with brief psychodynamic therapy (24 subjects) or medical treatment alone (25 subjects). Gastrointestinal symptoms, defense mechanisms, and alexithymia were assessed before the trial, after treatment, and at 1- and 12-month follow-ups. The results showed that brief psychodynamic therapy improved all of the gastrointestinal symptoms, including heartburn, nausea, fullness, bloating, upper abdominal pain, and lower abdominal pain, after treatment and at two follow

2013 Asian journal of psychiatry Controlled trial quality: uncertain

48. Ghrelin and Gastric Emptying in Children With Functional Dyspepsia

condition in children and adolescents. One of the most often diagnosed types of abdominal pain is functional dyspepsia (FD). FD is abdominal pain or discomfort (e.g., nausea, bloating) in the upper abdomen that does not get better by having a bowel movement. One possible explanation for having FD is a delay in the emptying of food from the stomach, or delayed gastric (stomach) emptying. Failing to empty the stomach quickly enough may result in the feeling of being full and cause symptoms of bloating (...) , nausea, vomiting and pain. Further, hormonal changes occur before, during, or after eating food that appear to impact stomach emptying. One of the hormones that changes with meals is called ghrelin. The relationship between ghrelin and stomach emptying needs to be explored more in children with FD. Better understanding of what causes FD symptoms may help us to improve treatment for this condition. Condition or disease Functional Dyspepsia Study Design Go to Layout table for study information Study

2012 Clinical Trials

49. Dyspepsia

, Functional Dyspepsia , Gastritis , Duodenitis , Acid-Related Dyspepsia From Related Chapters II. Definition Chronic or recurrent III. Epidemiology Dyspepsia overall : 40% of adults in U.S IV. Causes See See V. Pathophysiology Unclear etiology, however may be related to altered gastric motility often found in patients with Dyspepsia, but causality is not clear VI. Symptoms Epigastric burning, pain or discomfort Early satiety Associated symptoms (difficult to treat) and and Halitosis VII. Diagnosis: Rome (...) to higher doses Adjunctive medication options Metoclopramide (prokinetic agent) May offer benefit in Nonulcer Dyspepsia Risk of tardive diskinesia Ineffective Medications (avoid) Sucralfate offers no benefit in Nonulcer Dyspepsia Misoprostel offers no benefit in Nonulcer Dyspepsia XII. Approach: Step 4 - Consider Helicobacter Pylori testing Indications Lack of relief with empiric antisecretory therapy Undifferentiated Dyspepsia treatment does not benefit without ulcer However ulcer status unknown

2015 FP Notebook

50. The Clinical Significance of Acid Rebound in Functional Dyspepsia

Loedrup, Zealand University Hospital Study Details Study Description Go to Brief Summary: Proton pump inhibitors (PPI) have been shown to cause acid reflux related symptoms at withdrawal in healthy volunteers, a phenomenon known as Rebound Acid Hyper Secretion. Whether this also applies for patients with dyspeptic symptoms but without true reflux disease (functional dyspepsia) treated with PPI is unknown. If this is the case, it could lead to an unfortunate long term use of PPI, since the acid rebound (...) the primary endpoint (Development of GERD) but will be included in the analysis regarding one of the secondary endpoints (Effect of PPI on Functional Dyspepsia). Study subjects are randomized to either pantoprazol followed by cross over to placebo or to placebo. Escape medication in the form of Gaviscon can be used on demand. Internet based questionnaires are answered weekly. Questionnaires consist of the Gastrointestinal Symptom rating Scale (GSRS) in combination with items assessing postprandial

2011 Clinical Trials

51. Corticotropin Releasing Hormone (CRH) Responsiveness in Children With Functional Dyspepsia

of abdominal pain is functional dyspepsia (FD). FD is an abdominal pain or discomfort (e.g., nausea, bloating) in the upper abdomen that does not get better by going to the bathroom. For some people it appears that stress can make FD worse. In adults, stress can cause the release of a hormone called corticotropin releasing hormone (CRH). The release of CRH can cause abdominal pain by affecting how fast things move through a person's stomach and intestines. This makes the organs in the abdomen more (...) sensitive to pain, causing tenderness of the inside lining of the stomach and intestines. Different people react differently when the body releases CRH. Some people have abdominal pain without feeling any stress or anxiety while other people who have a lot of stress or anxiety don't have any abdominal pain. Some people have neither stress, anxiety, or abdominal pain when CRH is released into the body. In order to see how the bodies of children with functional dyspepsia and those without functional

2011 Clinical Trials

52. Duodenal perforation following esophagogastroduodenoscopy (EGD) with cautery and epinephrine injection for peptic ulcer disease: An interesting case of nonoperative management in the medical intensive care unit (MICU) (PubMed)

Duodenal perforation following esophagogastroduodenoscopy (EGD) with cautery and epinephrine injection for peptic ulcer disease: An interesting case of nonoperative management in the medical intensive care unit (MICU) The utilization of esophagogastroduodenoscopy (EGD) and related procedures continues to rise. Due to this increase in utilization is an inevitable rise in serious complications such as hemorrhage and perforation. One understudied and dreaded complication of EGD causing significant (...) morbidity and mortality is duodenal perforation.We present the case of a 63-year-old male who presented to our institution's emergency room with dyspepsia, melanic stools, tachycardia, and hypotension. Initial laboratory evaluation was significant for severe anemia, lactic acidosis, and acute kidney injury, while CT scan of the abdomen pelvis did not suggest retroperitoneal hematoma or bowel perforation. An emergent EGD was performed which showed multiple bleeding duodenal ulcers that were cauterized

Full Text available with Trip Pro

2015 International journal of surgery case reports

53. Dyspepsia

Dyspepsia Dyspepsia - Gastrointestinal Disorders - MSD Manual Professional Edition Brought to you by The trusted provider of medical information since 1899 SEARCH SEARCH MEDICAL TOPICS Common Health Topics Resources QUIZZES & CASES Quizzes Cases The trusted provider of medical information since 1899 SEARCH SEARCH MEDICAL TOPICS Common Health Topics Resources QUIZZES & CASES Quizzes Cases / / / / IN THIS TOPIC OTHER TOPICS IN THIS CHAPTER Test your knowledge Helicobacter pylori Infection People (...) illnesses but are less likely to... 3D Model GI Tract Video How to Insert a Nasogastric Tube SOCIAL MEDIA Add to Any Platform Loading , MD, Harvard Medical School Click here for Patient Education NOTE: This is the Professional Version. CONSUMERS: Topic Resources Dyspepsia is a sensation of pain or discomfort in the upper abdomen; it often is recurrent. It may be described as indigestion, gassiness, early satiety, postprandial fullness, gnawing, or burning. Podcast Etiology There are several common

2013 Merck Manual (19th Edition)

54. An unusual case of gastric outlet obstruction caused by tuberculosis: challenges in diagnosis and treatment (PubMed)

An unusual case of gastric outlet obstruction caused by tuberculosis: challenges in diagnosis and treatment Gastroduodenal tuberculosis (GDTB) is rare in the West. Its presentation can be non-specific and often mimics other more common conditions such as peptic ulcer disease, malignancy and Crohn's disease. Our case describes a 33-year-old Indian immigrant who presented with a 3-year history of dyspepsia and underwent balloon dilation for gastric outlet obstruction (GOO). While biopsies from (...) the duodenum revealed only non-caseating granuloma, a high index of suspicion was maintained and colonoscopy, performed despite the absence of lower gastrointestinal symptoms, revealed a single discrete nodular and ulcerated area in the proximal transverse colon; this eventually grew Mycobacterium tuberculosis. Our patient avoided undergoing major surgery and was successfully treated with balloon dilation and antitubercular medication. We highlight the importance of having a concerted, proactive approach

Full Text available with Trip Pro

2013 BMJ case reports

55. Pathogen-specific risk of chronic gastrointestinal disorders following bacterial causes of foodborne illness. (PubMed)

Pathogen-specific risk of chronic gastrointestinal disorders following bacterial causes of foodborne illness. The US CDC estimates over 2 million foodborne illnesses are annually caused by 4 major enteropathogens: non-typhoid Salmonella spp., Campylobacter spp., Shigella spp. and Yersinia enterocoltica. While data suggest a number of costly and morbid chronic sequelae associated with these infections, pathogen-specific risk estimates are lacking. We utilized a US Department of Defense medical (...) encounter database to evaluate the risk of several gastrointestinal disorders following select foodborne infections.We identified subjects with acute gastroenteritis between 1998 to 2009 attributed to Salmonella (nontyphoidal) spp., Shigella spp., Campylobacter spp. or Yersinia enterocolitica and matched each with up to 4 unexposed subjects. Medical history was analyzed for the duration of military service time (or a minimum of 1 year) to assess for incident chronic gastrointestinal disorders. Relative

Full Text available with Trip Pro

2013 BMC Gastroenterology

56. Evaluation and management of dyspepsia (PubMed)

Evaluation and management of dyspepsia Dyspepsia is a common clinical problem seen by both primary care physicians and gastroenterologists. Initial evaluation should focus on the identification and treatment of potential causes of symptoms such as gastroesophageal reflux disease (GERD), peptic ulcer disease, and medication side effects but also on recognizing those at risk for more serious conditions such as gastric cancer. This manuscript discusses the evaluation and management of dyspepsia (...) including the role of proton-pump inhibitors, treatment of Helicobacter pylori, and endoscopy. Finally, treatment of refractory functional dyspepsia is addressed.

Full Text available with Trip Pro

2010 Therapeutic advances in gastroenterology

57. Stroke and transient ischaemic attack in over 16s: diagnosis and initial management

guidance on off-label use of a medical device for further information. [7] Aspirin intolerance is defined as either of the following: proven hypersensitivity to aspirin- containing medicines, or history of severe dyspepsia induced by low-dose aspirin. [8] There may be a subgroup of people for whom the risk of venous thromboembolism outweighs the risk of haemorrhagic transformation. People considered to be at particularly high risk of venous thromboembolism include anyone with complete paralysis (...) of strok Prompt recognition of symptoms of stroke and tr e and transient ischaemic attack ansient ischaemic attack 1.1.1 Use a validated tool, such as FAST (Face Arm Speech T est), outside hospital to screen people with sudden onset of neurological symptoms for a diagnosis of stroke or transient ischaemic attack (TIA). [2008] [2008] 1.1.2 Exclude hypoglycaemia in people with sudden onset of neurological symptoms as the cause of these symptoms. [2008] [2008] 1.1.3 For people who are admitted

2019 National Institute for Health and Clinical Excellence - Clinical Guidelines

58. Patisiran for treating hereditary transthyretin amyloidosis

) amyloidosis is an ultra-rare condition caused by inherited mutations in the transthyretin (TTR) gene. This causes the liver to produce abnormal TTR protein, which accumulates as deposits in body tissues (amyloidosis). These deposits can disrupt the structure and damage the function of affected tissues. 2.2 Because hATTR amyloidosis can affect tissues throughout the body, people may have a range of symptoms relating to 1 or more systems. These can include the autonomic nervous system, peripheral nerves (...) polyneuropathy' . 3.2 The most common adverse reactions listed in the summary of product characteristics for patisiran include peripheral oedema, infusion-related reactions, infections, vertigo, dyspnoea, dyspepsia, erythema, arthralgia and muscle spasms. For full details of adverse reactions and contraindications, see the summary of product characteristics. 3.3 The price of patisiran is £7,676.45 per 10-mg vial (excluding VAT; company submission). The company has a commercial arrangement. This makes

2019 National Institute for Health and Clinical Excellence - Highly specialised technology

59. Peptic ulcer disease

Peptic ulcer disease Peptic ulcer disease - Symptoms, diagnosis and treatment | BMJ Best Practice You'll need a subscription to access all of BMJ Best Practice Search  Peptic ulcer disease Last reviewed: February 2019 Last updated: February 2019 Summary Peptic ulcers usually present as chronic, upper abdominal pain related to eating a meal (dyspepsia). Use of non-steroidal anti-inflammatory drugs (NSAIDs) and Helicobacter pylori infection are the most common causes. There may be some (...) M Meyer and Dr Steven Moss, previous contributors to this topic. Peer reviewers Consultant Gastrounit Medical Division Copenhagen University Hospital Hvidovre Copenhagen Denmark Disclosures LLG declares that she has no competing interests. Use of this content is subject to our Services Legal © BMJ Publishing Group 2018 ISSN 2515-9615 Help us improve Thank you × Your feedback has been submitted successfully.

2019 BMJ Best Practice

60. Cerebral palsy in under 25s: assessment and management

of pain, discomfort and distress identified in children and young people with cerebral palsy, treat the cause as appropriate using targeted interventions in line with the following NICE guidelines: spasticity in under 19s constipation in children and young people gastro-oesophageal reflux disease in children and young people and gastro- oesophageal reflux disease and dyspepsia in adults headaches in over 12s low back pain and sciatica in over 16s urinary incontinence in neurological disease urinary (...) Management 1.14.5 Optimise sleep hygiene for children and young people with cerebral palsy. 1.14.6 Manage treatable causes of sleep disturbances that are identified in children and young people with cerebral palsy. 1.14.7 If no treatable cause is found, consider a trial of melatonin [7] to manage sleep disturbances for children and young people with cerebral palsy, particularly for problems with falling asleep. 1.14.8 Do not offer regular sedative medication to manage primary sleep disorders in children

2017 National Institute for Health and Clinical Excellence - Clinical Guidelines

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>